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ABSTRACT 
The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly as a 
result of the obesity epidemic. T2DM develops in individuals who fails to 
compensate for increased demand of insulin. Obese individuals display 
alterations in the circulating lipid profile and there is evidence that the 
elevated levels of fatty acids are detrimental to pancreatic β-cells which may 
contribute to the progression of β-cell failure via both impaired function and 
a reduction of the β-cell mass seen in T2DM patients, but the mechanism is 
not completely known. There is evidence that saturated fatty acids can 
induce apoptosis, as well as endoplasmic reticulum (ER) stress. As a 
secretory cell, the pancreatic β-cell is equipped with a highly developed ER 
to assist in the folding process of newly synthesized proteins, but this cell 
organelle is sensitive to alteration in homeostasis, and an imbalance 
between protein load and folding capacity can result in ER stress. This thesis 
aimed to investigate the protein expression in insulin producing cells 
exposed to ER stress by the use of proteomics and Western blot. 
In paper I, cells were exposed to the ER stress inducer thapsigargin. By the 
use of proteomic methodology we found decreased levels of the ER 
localized proteins GRP78/BiP, PDIA3 and PDIA6 following thapsigargin 
treatment. The decreased protein levels of GRP78/BiP was not a 
concequence of reduced mRNA expression. Instead the decrease involved a 
combination of reduced protein synthesis and enhanced degradation by 
both proteasome and autophagy. The data in paper I provides an 
explanation to why INS-1E cells are vulnerable to conditions of ER stress. In 
paper II, cells were exposed to thapsigargin and the saturated fatty acid 
palmitate. By proteomic investigation we identified 7,786 proteins, of which 
6,117 were overlapping in two data sets. 1,000 proteins were regulated by 
thapsigargin and 227 by palmitate. With bioinformatic analysis we found a 
set of transcription factors predicted to be regulated in the same manner by 
the thapsigargin and palmitate. This paper shows that the treatments not 
only share the induction of ER stress but also share an effect on the lipid 
handling in the cell by affecting several metabolic master transcription 
factors involved in lipid and cholesterol biosynthesis. In paper III we 
investigated pathways involved in the cytotoxic action of glucocorticoids 
(GCs). Excess of GCs is associated with glucose intolerance and diabetes. The 
data show that GC activates p38 MAPK and JNK in β-cells, which work in 
opposite to regulate the cytotoxic effects induced by GCs. The data also 
suggests that protein phosphatase 5 play a protective role, since reduced 
PP5 levels in MIN6 cells and islets makes the cells sensitized to the toxic 
effects induced by GCs. Furthermore, our result indicate that GC exposure 
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compromises the cellular response to ER stress in insulin producing cells 
which may lead to an impaired capacity to restore the homeostasis in the ER 
A deeper understanding of the mechanisms and the mediators of the ER 
and apoptotic pathways will hopefully provide tools to preserve the β-cell 
mass and delay the progression to T2DM. 
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1 INTRODUCTION 
1.1 THE HISTORY OF DIABETES MELLITUS – FROM ANCIENT 
TIMES TO THE PRESENT 
Diabetes Mellitus is far from a new disease. Even the ancient Egyptians were 
suffering from it. The earliest known reference to what could be a 
description of diabetes mellitus was found in an Egyptian medical document 
called the Ebers Papyrus, written 1500 B.C. The hieroglyphs in this 
document describe a condition of “too great emptying of the urine” which 
could be the symptom of the excessive urination (polyuria) seen in patients 
suffering from diabetes mellitus.  Around the same time in India, physicians 
observed that urine from patients with polyuria attracted ants and flies, and 
named the condition “honey urine” [1]. Today we know that these are 
symptoms of a pronounced lack of insulin leading to high levels of glucose in 
the blood.  The name of the disease comes from the symptoms of the 
patient; Diabetes, which in Greek means “to pass through”, referring to the 
excessive amount of urine, and Mellitus from “honey-sweet”, referring to 
the excessive amount of sugar in the blood and urine. 
Before the discovery of insulin, diabetes mellitus was a deadly disease and it 
was not until the 19th century the first step to this discovery was done. In 
1869 Paul Langerhans described the histological structure of the pancreatic 
islets, but the function of these islets remained unknown for some years. 
When Oscar Minowski, in 1889, observed that removal of pancreas from 
dogs made them diabetic he established the connection between this organ 
and the control of blood glucose. The main breakthrough came when 
Frederick Banting and Charles Best in 1921 were able to extract insulin from 
pancreatic islets, and in 1922 the first diabetic patient, 14-year old Leonard 
Thompson, was injected with the extract. In 1923 the Nobel Prize was 
awarded for the discovery of insulin. Today insulin is the only medical 
treatment for people with type 1 diabetes mellitus (T1DM), the second most 
common form of diabetes, while people with type 2 diabetes mellitus 
(T2DM), the most common form of diabetes, may need insulin in later 
stages of the disease. 
Even though diabetes mellitus has been known for more than 3000 years 
the exact mechanism for the cause of the disease is still not known. In 
earlier years, T1DM was the mainly form of diabetes, but with the increased 
prevalence of obesity the number of individuals diagnosed with T2DM have 
bypassed the number of T1DM. The prevalence of diabetes has been rapidly 
increased in the last decades and the number of people with the disease has 
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more than doubled during the past 20 years. Today 382 million people are 
estimated to suffer from diabetes, a number predicted to increase to almost 
600 million by the year 2035 [2, 3], but still, 175 million cases are predicted 
to be undiagnosed [2]. Chronic hyperglycemia in undiagnosed people, or 
poorly managed diabetes in patients, is associated with severe and long-
term complications affecting several organs including eyes, kidneys, nerves, 
heart, and blood vessels [2]. In addition to the suffering for affected 
individuals, the economic burden of diabetes is enormous to health care 
systems. 
In later years, development of new techniques has brought knowledge of 
the development of diabetes forward by investigation of the genome and 
proteome. Genome-wide association studies have identified many 
susceptibility genes linked to diabetes mellitus, many of them expressed in 
pancreatic β-cells showing the importance for these insulin producing cells 
in the development of T2DM. With different proteomic methods it is 
possible to simultaneously analyze virtually all proteins expressed in a cell, 
and with these unbiased approaches it is possible to reveal novel findings 
that otherwise had not been identified, if a single pathway or a set of 
proteins decided beforehand, had been investigated. The aim of the present 
work was to add a few pieces to the complex puzzle underlying the 
development of T2DM by the use of proteomics in cells exposed to 
endoplasmic reticulum stress. 
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2 BACKGROUND 
2.1 DIABETES MELLITUS 
Diabetes is a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action or a combination of 
both [2]. The disease is classified into four different categories based on 
etiology and clinical features; I) Type 1 diabetes mellitus (T1DM), II) Type 2 
diabetes mellitus (T2DM), III) Other specific types of diabetes, and IV) 
Gestational diabetes mellitus (GDM) [4]. T1DM, also called insulin-
dependent diabetes, results from an autoimmune destruction of the insulin 
producing β-cells in pancreas leading to an absolute deficiency of insulin. 
The patients suffering from T1DM are therefore dependent on exogenous 
administration of insulin for their survival. The onset of disease usually 
occurs at young age. T2DM, also called non-insulin dependent diabetes, is 
the largest form of diabetes, accounting for ~90-95% of all cases of diabetes. 
Since the present thesis is focusing on T2DM, this category is further 
described in the next section. Other specific types of diabetes include 
genetic defects of the β-cell function or insulin actions, diseases of the 
exocrine pancreas, endocrinopathies, or induced by drugs or chemicals. 
GDM is diagnosed during pregnancy after development of resistance to 
insulin and subsequent hyperglycemia [4]. 
2.1.1 Type 2 diabetes mellitus 
As mentioned earlier, T2DM is the most common type of diabetes, 
nowadays accounting for ~90-95% of all cases of diabetes. The disease is 
usually associated with a relative lack of insulin (rather than an absolute 
deficiency as in the case of T1DM), often in combination with insulin 
resistance. Before diagnosis of T2DM, individuals can remain undiagnosed 
for many years because of the gradually developing hyperglycemia, which 
increases the risk for complications due to the long-term exposure to 
elevated glucose levels in the circulation. At the pre stage of the disease the 
circulating insulin levels can be high to compensate for a reduced insulin 
response. As the disease progress, the function of the β-cells become 
impaired and when the level of insulin not is enough to maintain 
normoglycemia, T2DM is a fact [4]. According to recommendations from 
World Health Organization (WHO) diabetes is diagnosed if the fasting 
plasma glucose is ≥7 mmol/L or the plasma glucose concentration is ≥11.1 
mmol/L two hours after an oral glucose load [5]. Clinical management of 
T2DM includes a combination of lifestyle interventions, with changes in diet 
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and increased physical activity [6], and pharmacological treatment which 
aims to increase the insulin secretion or increase the insulin sensitivity in 
peripheral tissue [7, 8]. In later stages of the disease, the patients may need 
insulin to control their blood glucose levels. 
The aetiology of T2DM is poorly understood but it results from a complex 
interplay between genetic predisposition and environmental factors. 
Genomic studies have so far identified approximately 70 genomic regions 
associated with T2DM [9, 10], but all of them together only explain a small 
part of the genetic background of the disease [11]. Most of these identified 
genes have been shown to be involved in pancreatic β-cell mass and/or 
function, associated to insulin secretion defects [12], showing the 
importance for these insulin producing cells in the development of T2DM. 
Environmental factors contributing to the development of the disease 
includes high caloric intake and a sedentary lifestyle leading to obesity, and 
as in the case of T2DM, the prevalence of obesity is also increasing across 
the world [13]. Obesity is strongly associated with increased risk of 
developing insulin resistance which leads to loss of insulin response in 
peripheral tissue [14, 15]. T2DM is a disease most common among adults 
but a worrying aspect is the rapid increase of T2DM in children and 
adolescents. As in adults, obesity and insulin resistance are risk factors for 
paediatric T2DM [16, 17]. Alterations in the circulating lipid profile have 
been observed in obese individuals [18, 19] and there is mounting evidence 
that the elevated levels of circulating free fatty acids can be detrimental to 
pancreatic β-cells which during long term effect may contribute to the 
progression of β-cell failure and T2DM [20-22]. 
2.1.2 The pancreatic islet and the insulin-producing beta-cell 
The pancreas is an organ consisting of both endocrine and exocrine tissue 
where the endocrine pancreas makes up only a small part of the whole 
pancreas (1-2% of total pancreas mass). These endocrine cells are organized 
in micro-organs called the islets of Langerhans. About one million islets are 
scattered throughout the pancreatic gland. The human islets consist of five 
different cell types with the insulin-producing β-cell representing the major 
part of the total cell mass in the islet [23, 24]. The remaining endocrine cell 
types in the islet are the glucagon-producing α-cell, the somatostatin-
producing δ-cell, the pancreatic polypeptide-producing PP-cell, and the 
ghrelin-producing ε-cell [25]. Together these cells cooperate to maintain the 
glucose homeostasis. 
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Approximately 50-80% of the cells in the islets are β-cells [25]. The β-cells 
develop from endocrine precursor cells that differentiate from epithelial 
progenitor cells in pancreatic ducts during prenatal life [26]. In humans the 
majority of β-cell expansion occurs in early childhood [27] where the highest 
rate of proliferation has been observed before 2 years of age [28, 29]. 
During adulthood the β-cell mass is highly adaptive to changes in metabolic 
homeostasis. When increased demand for insulin exists, such in the case of 
obesity [30], hyperglycemia or pregnancy [19], expansion of the β-cell mass 
has been shown to occur, to be able to secrete more insulin. 
2.1.3 Insulin synthesis and release 
Insulin is the key hormone required for maintenance of glucose homeostasis 
and as mentioned above, it is produced in and secreted from the β-cells in 
pancreas. The secretion of insulin is stimulated by intracellular signals 
obtained from metabolism of nutrients where glucose is the primary 
stimulus [31]. 
The human gene for insulin is located on chromosome 11. The synthesis of 
insulin starts with transcription of the insulin gene and subsequent 
translation of insulin mRNA into preproinsulin in the endoplasmic reticulum 
(ER) [1]. Insulin-producing β-cells (as well as other secretory cells) have a 
highly developed ER to meet the demand for the large amount of proteins 
to be synthesized by the cell [32]. In the ER, preproinsulin is cleaved to 
proinsulin by removal of the signal peptide. Proinsulin is packed into vesicles 
and transported to the trans Golgi network where it is converted to mature 
insulin by the action of prohormone-converting enzymes (PC1/3 and PC2). 
The mature insulin, in a crystalline form of six insulin molecules and two zinc 
atoms, and the C-peptide are stored in the granules until the β-cell get 
signals to release the content into the bloodstream [1]. 
Glucose is the main physiological regulator of insulin secretion in pancreatic 
β-cells, but the cells also respond to other nutrients such as amino acids and 
fatty acids. The glucose-stimulated insulin secretion (GSIS) generates a 
triggering and an amplifying pathway in the cell (also called the KATP-
dependent and KATP-independent pathways) [31, 33]. When the level of 
glucose in the blood is high, the triggering pathway starts with entering of 
glucose through specific glucose transporters (GLUT-1 in human and GLUT-2 
in rodents) in the β-cell [34, 35]. Glucose is then rapidly phosphorylated by 
glucokinase and further metabolized to pyruvate in series of enzyme-
catalysed reactions called the glycolysis. Pyruvate enters the mitochondria 
and is further metabolized in the tricarboxylic acid cycle (TCA cycle), 
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generating NADH and FADH2 which are used in the respiratory chain, for 
adenosine triphosphate (ATP) production. The increased ATP/ADP 
(adenosine diphosphate) ratio leads to closure of the KATP channels which 
result in membrane depolarisation and activation of voltage-dependent Ca2+ 
channels. Influx of Ca2+ into the cell increases the levels of cytoplasmic free 
Ca2+ which triggers fusion of a readily releasable pool (RRP) of insulin-
containing vesicles with the plasma membrane, resulting in a rapid release 
of insulin [36, 37]. This triggering mechanism is mainly responsible for a first 
phase of insulin secretory response, starting within minutes after glucose 
stimulation and lasts for 5-10 minutes [38] (Fig 1). When the RRP of insulin-
containing vesicles is depleted, it is refilled from a reserve pool (RP). 
 
Figure 1. Glucose-stimulated insulin secretion in the β-cell. (A) In the triggering 
pathway, glucose is transported into the cell through GLUT-1 (humans) or GLUT-2 
(rodents) and is metabolized to pyruvate which enters the mitochondria. In the TCA 
cycle ATP is yielded and the increased ATP/ADP ratio closes KATP channels. The 
subsequent depolarization of the membrane result in activation of Ca
2+
 channels, 
influx of Ca
2+
 and insulin release. The amplifying pathway augments the insulin 
secretion independent of the KATP channel. RRP (readily releasable pool), RP (reserve 
pool). (B) Insulin is secreted from the β-cell in a biphasic manner after glucose 
intake. The initial phase is rapid and dependent on generation of ATP and the 
subsequent influx of Ca
2+ 
in the triggering pathway. The second, prolonged phase is 
dependent on mitochondrial metabolism in the amplifying pathway. 
The amplifying pathway of GSIS augments the secretory response of insulin 
independent of the KATP channels. This pathway is mainly responsible for a 
second, more sustained, phase of insulin secretion which is gradually 
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increased over a period of 60 minutes [37]. The mechanisms involved in the 
amplifying pathway are not fully understood but several factors have been 
suggested where anaplerotic metabolism of pyruvate and efflux of TCA 
cycle intermediates are suggested as key events in this process [33, 39-41] 
(Fig 1). 
In healthy individuals, there is a balance between insulin secretion from 
pancreatic β-cells and insulin action in peripheral tissue to keep the blood 
glucose concentration within normal range (~5 mM). Several steps in the 
GSIS have been revealed to be impaired in type 2 diabetic patients. Loss of 
first phase of insulin secretion is an early pathogenic event in T2DM [42] and 
reduced insulin secretion from isolated islets from type 2 diabetic patients 
have been observed [43] as well as reduced expression of glucokinase in 
islets from T2DM donors [44]. As mentioned before, of the susceptibility 
genes associated with T2DM, most of these genes have been shown to be 
involved in pancreatic β-cell mass and/or function, associated to insulin 
secretion defects [12, 43]. 
2.1.4 Insulin signaling and regulation of blood glucose levels 
The main purpose of the insulin secreted by the pancreatic β-cells is to 
promote uptake of glucose in peripheral tissue and to suppress glucose 
production in the liver. Insulin initiates its biological actions by binding to 
the transmembrane insulin receptor (IR) on the surface of the target cell. 
The IR consists of two α-subunits and two β-subunits which are linked by 
disulphide bonds. Binding of insulin to the α-subunit results in 
autophosphorylation of the β-subunit and activation of insulin receptor 
substrate (IRS) 1 and 2 which can activate the phosphatidylinositol-3-kinase 
(PI3K) pathway, leading to translocation of glucose transporter 4 (GLUT-4) 
to the surface of the target cell. GLUT-4 is responsible for glucose transport 
from the blood into skeletal muscle and adipose tissue [1, 45]. Insulin and 
the glucose uptake stimulate glycogen synthesis in skeletal muscle, and 
promote lipogenesis and inhibit lipolysis in adipose tissue [15]. 
2.2 PANCREATIC BETA-CELL DYSFUNCTION 
Pancreatic β-cell dysfunction is central in T2DM pathogenesis [46] and is 
often associated with peripheral insulin resistance. Reduced sensitivity to 
insulin leads to an increased demand on the β-cell to secrete insulin in order 
to maintain glucose homeostasis. T2DM develops when the β-cell no longer 
can meet the secretory demand to maintain normoglycemia. Several 
mechanisms have been suggested to be involved in the progression of the 
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reduced β-cell function and β-cell mass and the mechanisms relevant to this 
work are describe below. 
2.2.1 Lipotoxicity in pancreatic beta-cells 
Lipids are normally stored in adipose tissue. When the supply of fatty acids 
(FA) overwhelms the storage capacity of adipose tissue, lipids accumulates 
in tissues other than adipose tissue, such as pancreas [47], where they exert 
harmful effects, a condition termed lipotoxicity [48]. Circulating free FAs are 
elevated in obese individuals [18, 19] and there is evidence that the 
elevated systemic levels of FAs are detrimental to pancreatic β-cells which 
may contribute to the progression of β-cell failure via both impaired 
function and reduction in β-cell mass seen in T2DM patients [21, 22, 49, 50]. 
Different fatty acids have different effects on the β-cells, where long-chain 
saturated FAs have been shown to be more toxic than both shorter 
saturated FAs and unsaturated FAs [50-52]. Palmitate (C16:0) is the most 
common saturated FA in plasma [18] and is therefore often used for 
investigation of the cytotoxic effects induced by FAs. The mechanisms 
causing the lipotoxic β-cell dysfunction and death are not completely 
understood, but several pathways have been shown to be affected, 
including ER stress [53] and autophagy [54]. In addition to the lipidemic 
environment in obesity, the progression to T2DM is also associated with 
high levels of glucose, leading to a glucolipotoxic environment for the β-cell 
[55, 56]. The glucolipotoxicity is associated with oxidative stress, induced by 
reactive oxygen species (ROS), generated during intracellular metabolism of 
glucose in the mitochondria which may cause damage to the mitochondrial 
DNA [57]. In addition, when glucose level is high, metabolism of glucose 
leads to flux of citrate from mitochondria and generation of malonyl-CoA in 
the cytosol. The increased level of malonyl-CoA inhibits the mitochondrial 
FA transporter carnitine palmitoyltransferase-1 (CPT-1) activity and stops 
FAs to enter the mitochondria for fatty acid β-oxidation. Instead, long-chain 
acyl-CoA accumulates in the cytosol where they directly or via generation of 
lipid derived signals negatively affects the β-cell function [50]. 
2.2.2 Apoptosis of pancreatic beta-cells 
Programmed cell death, or apoptosis, is a regulated process leading to 
death of the cell. Apoptosis is important for maintenance of cellular 
homeostasis during development but is also a defense mechanism to 
remove damage cells [58]. Apoptotic cell death is triggered by an extrinsic, 
receptor-mediated signaling pathway or an intrinsic, mitochondrial-
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mediated signaling pathway. The intrinsic pathway of apoptosis has been 
shown to be initiated by several insults, including DNA-damage, dysfunction 
of mitochondria (due to ROS or Ca2+ overload) and ER stress [58]. The 
protease family of caspases is the executors of cell death, but caspase-
independent mechanisms also exists [59]. 
The β-cell mass has been shown to be decreased in T2DM. Post-mortem 
investigations have reported a 30-60% decrease in β-cell mass in T2DM 
patients [30, 60-63] as a result of enhanced apoptosis [30, 64] associated 
with increased levels of caspase-3 and caspase-8 [65]. By the time of T2DM 
diagnosis estimations tells that about 50% of the functional β-cell mass is 
already lost [66]. The mechanisms involved in the apoptotic death of the β-
cells is not completely known but in vitro studies have shown that free FAs 
can induce the apoptotic pathway [53, 67].  A deeper understanding of the 
mechanisms and the mediators of the apoptotic pathway will hopefully 
provide tools to preserve the β-cell mass and delay the progression to 
T2DM. 
2.2.3 ER stress and ER stress induced beta-cell apoptosis 
The pancreatic β-cell synthesizes massive amounts of insulin. The 
translation of insulin mRNA in response to glucose stimulation has been 
shown to account for up to 50% of the total protein synthesis in the β-cells 
[68, 69]. As a secretory cell, the β-cell is equipped with a highly developed 
endoplasmic reticulum (ER) to assist in the folding process of newly 
synthesized proteins [70]. In addition to its function in protein synthesis, the 
ER is also involved in lipid and cholesterol metabolism [71] as well as it is a 
major cellular Ca2+ store compartment [72]. ER Ca2+ homeostasis is critical 
for ER function and proper folding of newly synthesized proteins [73]. To 
assist the folding process, ER contains chaperons including glucose-
regulated protein (GRP) 78 (also called BiP), GRP94, calnexin and 
calreticulin. In addition, these chaperones are part of the ER quality control 
system that target misfolded proteins for degradation [74]. Furthermore, ER 
contains protein disulphide isomerases (PDI), proteins that catalyses the 
protein folding process [75]. 
Several conditions can disturb the normal function of ER and lead to 
accumulation of unfolded or misfolded proteins, a condition termed ER 
stress. Protein overload, due to the rate of synthesis exceeds the rate of exit 
of proteins from ER, or alteration in the ER milieu that negatively affects the 
folding efficiency can lead to ER stress. To cope and survive under ER stress 
conditions, cells can induce a set of defence mechanisms collectively known 
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as the unfolded protein response (UPR) [76, 77]. UPR acts to reduce the 
amount of unfolded or misfolded proteins inside the ER through three 
major pathways: (1) translation attenuation, which prevents further 
accumulation of unfolded proteins; (2) up-regulation of genes encoding ER 
chaperones, to increase protein folding capacity; (3) degradation of 
misfolded proteins in the ER, called ER-Associated Degradation (ERAD) (Fig. 
2). These three pathways are each controlled by a specific protein: PKR-like 
eIF2α kinase (PERK), activating transcription factor 6 (ATF6) and inositol 
requiring enzyme 1 (IRE1) respectively. Under normal conditions these three 
UPR transducers are attached to and held inactive by the chaperone 
GRP78/BiP at the ER membrane. Accumulation of misfolded proteins in the 
ER causes release of GRP78/BiP which results in activation of these three 
proteins. Upon activation, PERK forms homodimers that becomes 
autophosphorylated and in turn phosphorylates and inhibits eIF2α 
(eukaryotic translation initiation factor 2, α subunit), leading to a reduced 
translation rate (Fig. 2). However, the translation rate of activating 
transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) is 
increased during phosphorylation of eIF2α (p-eIF2α). Growth arrest and 
DNA damage-inducible protein 34 (GADD34) activates a negative feedback 
loop to dephosphorylate eIF2α. When ATF6 is liberated from GRP78/BiP, it 
is detached from the ER membrane and transported to the Golgi where it is 
cleaved into a functional transcription factor by site 1- and site 2 proteases. 
This transcription factor promotes the expression of chaperones (Fig. 2). 
Finally, dimerization and autophosphorylation of IRE1 activates its 
endoribonuclease activity that targets the X-box-binding protein 1 (XBP-1) 
mRNA which is alternatively spliced (XBP-1s) and translated to a functional 
transcription factor that, together with ATF6, promotes the expression of 
chaperones and also enhances the expression of proteins involved in the 
ERAD pathway (further described in next section) (Fig. 2) [76, 77]. 
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Figure 2. The main components involved in UPR. Accumulation of unfolded 
proteins results in GRP78/BiP release from PERK, ATF6 and IRE1 which allows these 
proteins to become activated. Activation of PERK promotes phosphorylation and 
inhibition of eF2α, leading to a reduced translation rate. However, the translation 
rate of ATF4 and CHOP are increased during phosphorylation of eIF2α. GADD34 
activates a negative feedback loop to dephosphorylate eIF2α. Activation of IRE1 
activates its endoribonuclease activity, which cleaves the mRNA of XBP-1. Upon ER 
stress ATF6 is released from the ER membrane and transported to the Golgi where 
it is cleaved to a functional transcription factor by SP1 and SP2 proteases. 
 
If the UPR fails to relive cells from ER stress and restore ER homeostasis, the 
apoptosis program is activated [78, 79]. Apoptotic pathways triggered by ER 
stress include; transcriptional activation of the gene for CHOP by the PERK 
pathway of the UPR (and to some extent by ATF6), activation of caspase-12, 
and activation of the cJUN NH2-terminal kinase (JNK) pathway, by the IRE1 
pathway of the UPR (Fig. 3). Mechanistically, CHOP has been shown to 
promote apoptosis through inhibition of the anti-apoptotic protein Bcl2 [78, 
80, 81]. When the cell encounters ER stress, pro-apoptotic proteins from the 
Bcl2 family, Bak and Bax, undergo conformational changes in the ER 
membrane, allowing Ca2+ efflux from the ER. The increased concentration of 
Ca2+ in the cytoplasm activates the calcium dependent protease m-calpain 
which cleaves and activates procaspase-12, located in the ER membrane. 
Activated caspase-12 cleaves and activates procaspase-9 which leads to 
activation of the caspase cascade [77, 80, 82, 83]. Apoptosis via the JNK 
pathway starts with interaction between activated IRE1, TRAF2 (TNF 
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receptor-associated factor-2) and ASK1 (apoptosis signal-regulating kinase) 
which result in formation of the IRE1-TRAF2-ASK1 complex leading to JNK 
activation and cell death [84]. 
 
 
Figure 3. Apoptotic pathways induced by ER stress. Activated PERK (and to some 
part, activated ATF6) leads to increased expression of CHOP which inhibits the 
expression of Bcl2. Bak and Bax undergo conformational changes in the ER 
membrane allowing Ca
2+
 efflux from ER which activates the calcium dependent 
protease m-calpain leding to activation of procaspase-12 in the ER membrane and 
activation of the caspase cascade. Apoptosis via the JNK pathway starts with 
interaction between activated IRE1, TRAF2 and ASK1which results in formation of 
the IRE1-TRAF2-ASK1 and JNK activation. 
Recent investigations have shown that ER stress markers are present in β-
cells from type 2 diabetic patients [64, 79, 85] and in animal models of 
diabetes [79]. High glucose challenge of isolated islets from T2DM subjects 
showed increased mRNA levels of BiP/GRP78 and XBP1s compared to non-
diabetic controls [64]. Investigation of pancreatic sections from T2DM 
donors has revealed increased protein expression of BiP/GRP78, CHOP and 
DNAJC3 compared to non-diabetic controls, while isolated islets from db/db 
mice revealed an up-regulation of mRNA of a variety of ER stress markers, 
including XBP-1s, ATF4, CHOP, Hsp90b1, BiP/GRP78 and PDIA4 [79]. An 
additional study has reported  increased level of cytoplasmic CHOP, but also 
an increased nuclear translocation of CHOP in pancreas from T2DM donors 
compared to lean non-diabetic subjects [85]. In addition to the increased 
  21 
expression of ER stress markers, expansion of ER has been found, which is a 
hallmark of activated UPR [64]. What is known from studies conducted in 
clonal insulin secreting cells and isolated pancreatic islets is that saturated 
FAs activates parts of the UPR followed by increased rate of apoptosis [53, 
86, 87], but the triggering factor for FA-induced ER stress has not been 
identified. Investigations have shown that PERK and IRE1 signaling pathways 
of the UPR are strongly activated by palmitate [53]. ER stress has also been 
shown to be triggered by changes in ER Ca2+ handling induced by saturated 
FAs [53, 88] with depletion of ER Ca2+ and slower ER Ca2+ uptake. Since 
folding of proteins is a process dependent on Ca2+, the depletion leads to 
misfolding of the newly synthesized proteins. Palmitate also hampers the 
trafficking of proteins from ER-to Golgi leading to additional accumulation of 
proteins in ER [89]. 
2.2.4 Protein degradation pathways in pancreatic beta-cells 
ER stress and a compromised UPR can lead to accumulation of unfolded or 
misfolded proteins in the cell. Removal of the accumulated proteins is 
necessary before reaching toxic levels. Two main systems exist to degrade 
these proteins; the ERAD pathway and autophagy. A proper function of 
these pathways is necessary to maintain cellular homeostasis and a normal 
function of the cell. 
2.2.4.1 ER-Associated Degradation pathway in beta-cells 
The ERAD pathway for degradation of misfolded proteins is strongly 
connected to ER stress since this pathway is induced by the IRE1 pathway of 
the UPR. In addition to protein folding, the ER also compromises a quality-
control system that recognizes misfolded proteins in the ERAD pathway and 
targets them for degradation in the ubiquitin-proteasome system, to 
protect the cell from ER stress [90]. In the ERAD pathway terminally 
misfolded proteins are translocated across the ER membrane into the 
cytoplasm where they are covalently bound to ubiquitin. Attachment of 
multiple ubiquitins gives a polyubiquitin chain, a signal for degradation by 
the proteasome [91]. Incubation of human and rodent islets, and MIN6 β-
cells, with a proteasome inhibitor, resulted in a significant reduction in 
glucose-induced insulin secretion showing the importance for a functional 
proteasome in normal β-cell physiology [92-94]. Accumulation of 
polyubiqutinated proteins and low expression of the deubiquitinating 
enzyme ubiquitin C-terminal hydrolase L1 in islets from type 2 diabetic 
patients has also been reported [95]. Consistent with this, one more report 
showed accumulation of ubiquitinated proteins, but also a reduced 
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proteasomal activity and down-regulation of genes in the ubiquitin-
proteasome system in islets from type 2 diabetic patients [96]. In addition to 
this, palmitate reduced the proteasomal activity in non-diabetic islets and 
INS-1E cells [96]. These reports show the importance of a functional 
ubiquitin-proteosomal system to protect the cell from ER stress. 
2.2.4.2 Autophagy in beta-cells 
Autophagy is a catabolic process that involves the degradation of proteins 
and organelles through the lysosomal machinery [97]. The autophagic 
process involves rearrangement of subcellular membranes, sequestering 
the proteins or organells destined for degradation, forming a double-
membrane structure called autophagosome. The autophagosome fuses 
with the lysosome, forming the autolysosome, where the cargo is degraded 
by hydrolases, and the resulting macromolecules are released back to the 
cytosol [97]. Basal autophagy occurs at low rate in all eukaryotes to clear 
damage organelles, proteins and aggregates. Investigation of islets from 
type 2 diabetic donors has shown increased numbers of autophagosomes 
[98]. The accumulation of autophagosomes was suggested to be a result of 
defects in the lysosomal step of autophagy, indicated by decreased 
expression of genes involved in this, late step [98]. In addition, exposure of 
non-diabetic islets to FAs also led to accumulation of autophagosomes and 
reduced expression of genes in the late, lysosomal, step [98]. Several 
investigations of rodent islets and β-cells has also revealed that exposure to 
FFAs accumulates autophagosomes [54, 99-102]. ER stress has been 
suggested to be involved in the mediation of autophagy, since the synthetic 
chaperone 4-PBA partially abolished the induction of autophagy by FFAs in 
INS-1 cells [101]. In vivo investigations in mice with β-cell-specific disruption 
of the autophagy-related gene (Atg7), required for autophagy, have shown 
increased apoptosis and reduced proliferation, resulting in a reduction in 
the β-cell mass [103, 104]. Most investigations suggests that autophagy 
function as a protective mechanism, to restore the homeostasis during 
cellular stress, but it has also been suggested that autophagy may function 
as an executor of cell death [105]. 
2.3 THE METABOLIC SYNDROME 
The metabolic syndrome is a medical term for a collection of abnormalities 
including glucose intolerance, hypertension, dyslipidemia and obesity, 
particularly abdominal obesity, which in combination increase the risk for 
T2DM and cardiovascular disease [106]. The prevalence of the metabolic 
syndrome is, as in the case of T2DM, increasing worldwide due to increased 
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energy intake, sedentary lifestyle and increasing obesity. The metabolic 
syndrome shares many of its abnormalities with conditions of elevated 
levels of the steroid hormone cortisol, including glucose intolerance [107] 
hypertension, abdominal obesity and dyslipidemia [108, 109], which can 
lead to T2DM. In addition, individuals suffering from metabolic syndrome 
have also been shown to have elevated levels of the cortisol [110-112]. It 
has therefore been suggested that the disturbed regulation of secretion and 
action of cortisol are involved in the progression of the metabolic syndrome 
[113, 114]. 
2.3.1 Glucocorticoids and steroid induced diabetes 
Glucocorticoids (GCs), such as cortisol in humans and corticosterone in 
rodents, are steroid hormones produced by the adrenal cortex. These 
hormones exert their function in different target tissues by binding to either 
the GC receptor (GR) or the mineralocorticoid receptor [115]. The main 
physiological role of the GC hormone is to increase the level of glucose in 
the circulation by several mechanisms including, increased gluconeogenesis 
in the liver, decreased uptake of glucose into muscle and adipose tissue, 
breakdown of proteins and lipids to provide additional substrates for 
glucose production, and inhibition of insulin secretion from pancreatic β-
cells [116-118]. 
Conditions of steroid induced diabetes [115] have been shown to develop in 
individuals with Cushing´s syndrome, a condition of endogenous 
overproduction of GCs by the adrenal cortex [119] together with the 
abnormalities, in the case of metabolic syndrome, described above. In 
addition, synthetic GCs, such as dexamethasone, that are commonly 
prescribed for numerous pathological conditions, including inflammation, 
autoimmune diseases and cancer [115, 120] have side effects of reduced 
insulin sensitivity, glucose intolerance and even frank diabetes [121].  
Investigations performed in isolated islets and pancreatic β-cell lines have 
shown that exposure to GCs are toxic to these cells [122-124], but how the 
GCs exert their cytotoxic action in the β-cells is not fully understood. 
Investigations have suggested ER stress and modulation of the UPR [125], as 
well as p38 MAPK activation and subsequent up-regulation of thioredoxin-
interacting protein [124], as possible contributors to the cytotoxic action of 
the GCs in pancreatic β-cells. 
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2.4 PROTEOMICS IN BETA-CELL RESEARCH 
Proteins are the key mediators of all cellular processes. The composition of 
a protein is determined by its genetic code, contained within the DNA, 
which is replicated and transcribed into mRNA, and further translated to 
protein, a process called the central dogma [126] (Fig.4). 
 
Figure 4. The central dogma of molecular biology. The central dogma involves the 
processes of replication, transcription and translation. 
T2DM is a complex disease with altered expression of many genes and their 
products [12, 127]. To explore these complex changes in pancreatic β-cell, 
different research strategies have been used, including investigation of the 
genome, transcriptome and proteome. The entire set of genes in a cell is 
called its genome, and the large-scale study of the genome is called 
genomics. A genome is constant which means that all cells within an 
organism contain the same set of genes where the DNA is constant, and it is 
therefore not possible to investigate dynamic changes in response to 
various internal or external stimuli in the DNA sequence. However, recent 
progress in the field of epigenetics has revealed that modifications in, for 
example DNA methylation, can be induced by environmental changes [128]. 
In contrast to the genome, alterations of the gene expression can be 
measured at the mRNA level. The transcribed genes at a given time in a 
sample are called the transcriptome. Transcriptome analysis have generated 
detailed information on the gene expression in, for example β-cells [127]. 
However, limitations in the investigation of the transcriptome exist. These 
include the inability to investigate post-translational modifications that 
sometimes is necessary for the function of a protein [129]. Furthermore, the 
correlation between the levels of mRNA and its corresponding protein has 
been reported to be rather weak [130, 131]. These limitations can be 
avoided by investigation of the proteins, which are the mediators of the 
cellular processes. 
All expressed proteins within a cell make up the proteome [132], and the 
research area in which proteins are studied on a large-scale is called 
proteomics. The human genome contains approximately 20,000 genes, each 
coding for one or more specific protein [133]. The corresponding number of 
proteins and their isoforms after post-translational modifications are 
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estimated to be around 1 million [134], making the proteome extremely 
complex. Thus, proteomics research can be a challenging task.  
2.4.1 Proteomic studies performed in pancreatic islets and 
insulin producing clonal cells. 
For the endocrine pancreas, proteomic profiling via two-dimension gel 
electrophoresis (2DGE) of isolated pancreatic islets has resulted in reference 
maps of both mouse [135] and human [136] islets, which identification 77 
and 66 proteins respectively. A proteome reference map of INS-1E cells 
resulted in 331 unique proteins [137]. These investigations were performed 
by the use of 2DGE followed by identification with mass spectrometry (MS). 
A more recent study using LTQ-Orbitrap MS identified approximately 2000 
proteins in a single islet [138]. Transcriptomic and antibody-based profiling 
analysis of in vitro isolated endocrine islets identified a set of 42 genes with 
elevated, compared to any tissue, in these specialized cells [139]. In addition 
to profiling of cells and islets, investigations of mechanisms contributing to 
β-cell failure have been performed both in vivo [140] and in vitro [67, 141-
146]. In a study performed in human islets using surface enhanced laser 
desorption/ionization (SELDI) MS technique to compare the difference in 
the proteome between isolated islets from T2DM patients and controls, 
approximately 20 proteins were differentially changed in in islets from 
T2DM patients. Several pathways, including apoptosis, immune-response 
and regeneration were suggested to be activated in the T2DM islets [141]. 
In another study, Han et al. used the iTRAQ technique to compare islets 
from Zucker lean (ZL), ZF and ZDF rats, representing control, 
obese/prediabetes and obese/diabetes conditions, respectively [140]. A 
total of 54 and 58 proteins were differentially expressed in ZDF versus ZL 
and in ZF versus ZL, respectively. Among the potential factors mediating the 
progress from a prediabetic state to T2DM, impaired insulin secretion, 
mitochondrial dysfunction, and dysregulation of triglyceride/free FA cycling 
were identified by this study [140]. A proteomic approach has also been 
used to investigate the effects of high glucose in INS-1E cells [142]. 2DGE MS 
revealed 100 differentially expressed proteins compared to the control, 
involved in different pathways. Following high glucose, chaperone proteins 
were down-regulated, protein biosynthesis and ubiquitin-related 
proteosomal degradation were attenuated, as well as perturbations in 
secretion, intracellular trafficking and vesicle transport were observed [142]. 
Proteomics has been used for investigation of the impact of ER stress on 
pancreatic β-cells [143]. INS-1E cells were exposed to high and low 
concentrations of the ER stress inducer cyclopiazonic acid (CPA). Exposure 
to high concentration of CPA led to massive apoptosis and down-regulation 
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of proteins involved in insulin processing and chaperones, including 
BiP/GRP78 and PDIA3 [143]. 
Different proteomic approaches have also been applied to investigate the 
effect of palmitate in β-cells. A 2DGE-based study in INS-1E cells identified 9 
proteins, related to glycolysis, ER stress and the proteasome,  to be 
regulated by palmitate [144]. Using SELDI MS and 2DGE approaches in INS-
1E cells exposed to palmitate, CPT-1 where shown to be up-regulated and 
calmodulin down-regulated [145]. Another 2DGE-based investigation in 
human islets and MIN6 cells identified carboxypeptidase E as a protein 
down-regulated by palmitate exposure [67]. Functional investigations 
showed that degradation of carboxypeptidase E contributes to ER stress and 
apoptosis following palmitate exposure [67]. These proteomic investigations 
have detected a relatively low number of proteins affected by palmitate. 
One possible explanation could be that palmitate mainly affects low 
abundant proteins which can be difficult to detect by gel-based methods. To 
be able to identify a larger number of proteins affected by palmitate Maris 
et al. reduced the complexity of the sample by subcellular prefractionation 
[146]. Since palmitate acts, at least in part, through ER stress they used the 
ER enriched fraction for their investigation, as well as full cell lysate, from 
INS-1E cells. In the full cell lysate, 5 proteins were found to be affected by 
palmitate, while the ER enriched fraction resulted in identification of 18 
proteins regulated by palmitate. The investigation showed that palmitate 
induced β-cell dysfunction and death via ER stress, hampered insulin 
maturation, generation of harmful metabolites during triglyceride synthesis 
and altered intracellular trafficking [146]. 
The use of proteomics in β-cell research have provided important insights 
into the pathways and proteins, in various conditions connected to 
diabetes, which may be involved in the dysfunction of the β-cells leading to 
T2DM. 
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3 AIMS OF THE THESIS 
 
The general aim of this thesis was to investigate the protein expression in 
insulin producing cells exposed to endoplasmic reticulum stress. 
 
 
The specific aims were: 
Paper I:  To investigate the chaperone expression during an ER stress 
response, induced by thapsigargin in the pancreatic β-cell 
line INS-1E, by the use of quantitative mass spectrometry 
based proteomics. We also wanted investigate by which 
mechanisms thapsigargin decreased GRP78/BiP protein in 
these cells. 
Paper II:  To investigate the cellular protein changes in the pancreatic 
β-cell line INS-1E exposed to the saturated fatty acid 
palmitate and compare those to changes induced by the ER 
stress inducer thapsigargin by the use of quantitative mass 
spectrometry based proteomics. 
Paper III:  To investigate pathways involved in the cytotoxic action of 
glucocorticoids and the role of mitogen-activated protein 
kinases and protein phosphatase 5 in this process in 
pancreatic β-cells and islets. 
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4 MATERIALS AND METHODS 
 
4.1 CULTURE AND TREATMENT OF CELLS AND ISLETS 
4.1.1 INS-1E cells 
Rat insulinoma, INS-1E, cells [147] (paper I and II), kindly provided by 
Professor Claes Wollheim, are derived from rat pancreatic β-cells and were 
maintained in RPMI-1640 medium (SVA, Uppsala, Sweden) containing 11 
mM glucose supplemented with 10% FBS (Invitrogen, Carlsbad, CA), 10 mM 
HEPES (Invitrogen), 2 mM L-glutamine (SVA), 1 mM sodium pyruvate 
(Sigma-Aldrich, St. Louis, MO), 50 µM β-mercaptoethanol (Sigma-Aldrich) 
and antibiotics (6 mg/ml pencillin G and 5 mg/ml streptomycin sulfate 
[Invitrogen]) at 37˚C in a humidified atmosphere containing 5% CO2. Cells 
were used between passages 71 and 80. 
4.1.2 MIN6 cells 
Mouse insulinoma, MIN6, cells [148] (paper I and III), kindly provided by Dr. 
Jun-ichi Miyazaki, are derived from mouse pancreatic β-cells and were 
maintained in DMEM medium (Invitrogen) containing 25 mM glucose 
supplemented with 15% FBS, 2 mM L-glutamine, 50 µM β-mercaptoethanol 
and antibiotics (6 mg/ml pencillin G and 5 mg/ml streptomycin sulfate) at 
37˚C in a humidified atmosphere containing 5% CO2. Cells were used 
between passages 22 and 30. 
4.1.3 Pancreatic islets 
Islets of Langerhans isolated from 3 to 6 month old male Wistar rats (paper 
I), C57Bl/6J mice (Scanbur, Sweden) (paper I and III), ob/ob mice (local 
breed, C57Bl/6J background) (paper III) and PP5 knockout (Ppp5c-/-, local 
breed, C57Bl/6J background) mice (paper III) were used. Animals were 
sacrificed by exposure to CO2 followed by decapitation. The pancreatic 
glands were excised and islets were isolated by collagenase digestion 
(Roche, Roche Diagnostics GmbH, Mannheim, Germany) and cultured in 
RPMI-1640 culture medium containing 11 mM glucose supplemented with 
10% FBS, 2 mM L-glutamine, and antibiotics (6 mg/ml pencillin G and 5 
mg/ml streptomycin sulfate) for overnight recovery at 37˚C in 5% CO2. 
Animal handling was performed according to national law and approved by 
local ethical committee. 
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4.1.4 Treatment of cells and islets 
Cells were plated 72 hours prior to treatment, and treatment of islets was 
started the day following isolation. The reagents used were: ER stress 
inducer thapsigargin (Sigma-Aldrich) (paper I and II), proteosome inhibitor 
lactacystin (Calbiochem, San Diego, CA) (paper I), autophagy inhibitor 3-
methyladenine (3-MA) (Sigma-Aldrich) (paper I), and protein synthesis 
inhibitor cycloheximide (Sigma-Aldrich) (paper I). The GCs dexamethasone, 
prednisolone, triamcinolone, betamethasone, the GR antagonist RU486 
(Sigma-Aldrich), the p38 MAPK inhibitor SB203508, and the JNK inhibitor 
SP600125 (Calbiochem) were all used in paper III. The saturated fatty acid 
palmitate was used to treat cells in paper II. Palmitate was prepared in 
12.5% ethanol as 100 mM stock solutions. Prior to treatment, palmitate was 
allowed to complex with fatty acid-free BSA (Roche) for 30 minutes at 37 °C. 
Treatment of cells were performed in identical medium as the culture 
medium with the exception for paper II were the FBS concentration was 1% 
and the medium supplemented with 0.5% fatty acid-free BSA. 
4.2 PROTEIN EXTRACTION, SDS-PAGE AND WESTERN BLOT 
ANALYSIS 
Western blot is used to detect specific proteins in a sample. The proteins are 
separated according to their molecular weight by the use of sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Western blot were 
used to measure protein abundance in all three papers. Treated INS-1E cells 
and MIN6 cells were washed in PBS and lyzed on ice for 30 minutes in buffer 
containing 150 mM NaCl, 20 mM Tris, 0.1% SDS, 1% Triton X-100, 0.25% Na-
deoxycholate, 1 mM Na3VO4, 50 mM NaF, 2 mM EDTA and Protease 
inhibitory cocktail (Sigma-Aldrich). After lysis, the preparation were 
collected and centrifuged at 14.000g for 15 minutes at 4 °C. Isolated islets 
were sonicated following the lysis in the buffer described above. Protein 
concentration was determined with Bio-Rad DC protein assay (Bio-Rad 
Laboratories, Hercules, CA). Equal amounts of protein were separated by 
10-15 % SDS-PAGE and transferred to Immun BlotTM PVDF membranes 
(Bio-Rad Laboratories). Immunoblot analysis was performed using primary 
antibodies against GRP78/BiP, phosphorylated GR (serine 220), total GR 
(Abcam, Cambridge, UK), p-eIF2α, eIF2α, p-JNK, JNK, LC3B, cleaved caspase 
3, phosphorylated p38 MAPK, total p38 MAPK (Cell Signaling Technology, 
Danvers, MA), CHOP, Chromogranin-A, cleaved spectrin α II, p53, SREBP-1, 
SREBP-2 , FOXO1, FOXM1, PP5, phosphorylated ASK-1 and total ASK-1 
(Santa Cruz Biotechnology, Santa Cruz, CA). Horesradish peroxidase-
conjugated goat anti-rabbit IgG and goat anti-mouse IgG were used as a 
secondary antibody (Santa Cruz Biotechnology). The protein-specific signals 
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were detected using Enhance Chemiluminescence (ECL) (GE-healthcare, 
Faifield, CT). The signals were imaged quantified using Molecular Imager 
ChemiDoc XRS with Quantity One Software v. 4.6.5 (Bio-Rad Laboratories). 
Coomassie Brilliant Blue (BioRad Laboratories) was used for staining of 
membranes for total protein normalization. 
4.3 PROTEOMIC ANALYSIS 
4.3.1 Preparation of samples 
Paper I. After exposure, cells were washed, lyzed and protein concentration 
measured as proteins extracted for Western blot. Equal amounts of protein 
from each treatment condition were acetone-precipitated. The pellets were 
dissolved in dissolution buffer containing triethylammonium bicarbonate 
from the iTRAQ 8-plex kit (Applied Biosystems, Foster City, CA). Denaturant 
containing SDS from the iTRAQ kit was added; proteins were reduced by 
adding tris-(2-carboxyethyl) phosphine and alkylated by methyl 
methanethiosulfonate (MMTS) from the iTRAQ kit. After denaturation, 
reduction and alkylation, proteins were digested with trypsin (TPCK treated, 
Applied Biosystems). Trypsin was added, 1:50, trypsin:protein, and 
incubated overnight at 37 °C followed by determination of the peptide 
concentration. 
 
Paper II. After exposure, cells were harvested by trypsination and washed in 
PBS. Cells were lysed in buffer containing 4 % SDS, 25 mM HEPES, 1 mM DTT 
and Protease inhibitory cocktail (Sigma-Aldrich), heated at 95 C for 5 min 
followed by sonication. The lysate was centrifuged for 30 mininutes at 
14,000 g followed by determination of protein concentration. Equal 
amounts of protein (200 μg) from each treatment condition were mixed 
with 8 M urea (Sigma-Aldrich), 1 mM DTT, 25 mM HEPES, pH 7.6, in a 
centrifugation filtering unit, 10 kDa cutoff (Nanosep® Centrifugal Devices 
with Omega™ Membrane, 10 k), and centrifuged for 30 minutes at 14,000 g, 
followed by another addition of 8 M urea buffer and centrifugation. Proteins 
were alkylated by 50 mM iodoacetamide (Sigma-Aldrich) in 4 M urea, 25 
mM HEPES, pH 7.6, for 10 minutes incubation at room temperature and 
centrifugation for 30 minutes at 14,000 g, followed by 2 more additions of 4 
M urea and 25 mM HEPES, pH 7.6, and centrifugations for 30 minutes at 
14,000 g. Trypsin (TPCK-treated, Applied Biosystems), 1:50, trypsin:protein, 
was added to the samples in 0.25 M urea, 25 mM HEPES and digested 
overnight at 37 °C. The filter units were centrifuged for 30 min, 14,000 g, 
followed by another centrifugation with milli-Q water and the flow-through 
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was collected. Peptide concentration was determined with Bio-Rad DC 
protein assay. 
4.3.2 iTRAQ labeling 
iTRAQ (Isobaric tag for relative and absolute quantification) are tags used 
for mass spectromey based quantification of changes in the proteome 
(paper I and II). iTRAQ 8-plex tags consists of a reporter group ranging from 
113-121 Da (except for 120 Da) and a balancing group making the tags 
identical in mass and chemistry (Fig. 5). 
Figure 5. iTRAQ labeling for relative quantification of peptides. Cells were exposed 
and proteins were extracted and digested. The peptides were labeled with eight 
different isobaric tags and the samples were pooled. Peptides were then separated 
using nano-LC (paper I) or IEF and nano-LC (paper II). MALDI-MS/MS (paper I) or 
ESI-MS/MS (paper II) were used to identify proteins in the sample by peptide 
sequencing. The relative abundance of each peptide was estimated by the peak 
intensities of the eight different reporter groups. 
 
 iTRAQ labeling of the peptides was done according to the manufacturer’s 
protocol (Applied Biosystems, Foster City, CA) and excess reagent and 
detergents were removed by strong cation exchange solid phase extraction, 
strata-X-C-cartridge System (Phenomenex Inc, Torrance, CA). 
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4.3.3 Separation of peptides 
4.3.3.1 Isoelectric focusing 
In isoelectric focusing (IEF), proteins or peptides are separated based on 
their isoelectric point (pI). This is performed by applying the proteins or 
peptides on an immobilized pH gradient (IPG) gel. An applied electrical 
current result in migration of the proteins or peptides in the IPG gel until the 
net charge is zero. This pre-fractionation step reduces the complexity of the 
sample and thus increases the proteome coverage. The iTRAQ-labeled 
peptides in paper II were pre-fractionation based on their pI on a narrow 
range pH 3.7-4.9 strip. Peptides were extracted from the strips in 72 
fractions with MilliQ water using a prototype liquid-handling robot (GE 
Healthcare Bio-Science AB). Extracted peptides were dried in speed vac and 
dissolved in 3 % acetonitrile, 0.1% formic acid. Peptides were further 
separated by nano- liquid chromatography (LC) before mass spectrometry 
analysis. 
4.3.3.2 Nano-Liquid Chromatography 
Nano-Liquid Chromatography (LC) is used for separation of peptides and 
cleaning of the sample prior to the mass spectrometry analysis. We have 
used the reversed phase method which is based on the peptides interaction 
with a hydrophobic matrix (C18 column). The peptides bind to the matrix in 
the presence of a highly polar solvent such as water. Gradual addition of a 
non-polar solvent separates the peptides according to their polarity. 
Paper I. Peptides were separated on an Ultimate 3000 LC system. Samples 
were trapped on a Symmetry C18, 100 Å, 5 µm, 180 µm x 23,5 mm trap 
column, and separated on a XBridge BEH130 C18, 3.5 µm, 75 µm x 150 mm 
nanoease column using a gradient of A (3 % ACN, 0.05 % TFA) and B (80 % 
ACN, 0.04 % TFA) ranging for 0 % to 45 % B in 150 min at a flow of 0.3 
µl/min. 
Paper II. Peptides were separated on an Agilent 1200 nano-LC system. 
Samples were trapped on a Zorbax 300SB-C18, and separated on a NTCC-
360/100-5-153 column (Nikkyo Technos., Ltd) using a gradient of A (3 % 
ACN, 0.1 % FA) and B (95 % ACN, 0.1 % FA), ranging from 3 % to 40% B in 50 
or 90 min with a flow of 0.4 µl/min. 
  33 
4.3.4 Mass spectrometry 
Mass spectrometry (MS) is a method that is used to determine the mass of a 
molecule. The instrument separate ions in gas phase based on their mass-
to-charge ratio (m/z). With the use of tandem MS (MS/MS), the sequence of 
the molecules can be revealed by fragmentation of the sample. The three 
major component of a mass spectrometer are the ion source, where the 
peptides become ionized, the mass analyzer that determine the m/z, and 
the detector that register the number of ions at each m/z value. Different 
mass spectrometry equipment has been used in paper I and II. 
4.3.4.1 MALDI-TOF/TOF 
The peptides in paper I were analyzed with MALDI-TOF/TOF (Matrix assisted 
laser desorption ionization – Time of Flight/Time of Flight) (Applied 
Biosystems). MALDI is an ion source where the sample and a matrix, which 
absorb laser energy, co-crystallize on a target plate. Irradiation of the 
crystals results in ionization of the peptides, and the ions enter the mass 
analyzer. The TOF mass analyzer separate ions based on the time the ion 
take to move from the source to the detector. The first TOF MS isolate 
precursor ions and the second TOF MS analyze the fragmented ions. In our 
analysis, data were acquired in positive reflector mode over a mass range of 
700-4000 m/z using external calibration spots with BSA digests. Mass 
spectra were obtained from each spot using fix laser intensity, 2000 shots 
per spectrum, with a uniformly random spot search pattern. A 1 kV MS/MS 
operating mode was used, the relative precursor mass window was set at 
200 (FWHM). Collision induced dissociation (CID) fragmentation of peptides, 
when they collide with gas molecules, using air, was turned on, with 
metastable suppression enabled. Peaks with a signal/noise (S/N) ratio 
greater than 70 were selected for MS/MS. Up to 20 MS/MS spectra could be 
obtained from each spot, starting with the least intense peak and ending 
with the most intense peak. MS/MS acquisition of selected precursors was 
set to a minimum of 1500 shots per spectrum and a maximum of 2000 shots 
with 40 shots per sub-spectrum. The stop criteria were set to minimum of 
15 peaks with a minimum S/N of 100 within the spectrum. 
4.3.4.2 ESI-LTQ-Orbitrap 
The peptides in paper II were analyzed with ESI- LTQ -Orbitrap Velos 
(Electrospray ionization-Linear quadropole ion trap) (Thermo Fischer 
Scientific, San Jose, CA). ESI generates ions in gas phase, from a sample in 
liquid phase, by applying a high voltage. The LTQ-orbitrap is a hybrid 
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instrument with two different mass analyzers. In the LTQ, ions are trapped, 
and peptide identification is generated by CID. In addition to the 
fragmentation by CID, the LTQ-Orbitrap includes high resolution ion 
detection with the use of higher-energy collisional dissociation (HCD). In our 
analysis, the instrument was operated in a data-dependent manner, 
selecting 5 precursors for sequential fragmentation by CID and HCD, and 
analyzed by the linear iontrap and orbitrap, respectively. The survey scan 
was performed in the Orbitrap at 30,000 resolution (profile mode) from 
300-2000 m/z, using lock mass at m/z 445.120025, with a max injection time 
of 500 ms and AGC set to 1 x 106 ions. For generation of HCD fragmentation 
spectra, a max ion injection time of 500 ms and AGC of 5 x 104 were used 
before fragmentation at 50 % normalized collision energy. For FTMS MS2 
spectra, normal mass range was used, centroiding the data at 7500 
resolution. Peptides for CID were accumulated for a max ion injection time 
of 200 ms and AGC of 3 x 104, fragmented with 35 % collision energy, 
wideband activation on, activation q 0.25, activation time 10 ms before 
analysis at normal scan rate and mass range in the linear iontrap. Precursors 
were isolated with a width of 2 m/z and put on the exclusion list for 90 s. 
Single and unassigned charge states were rejected from precursor selection. 
4.3.5 Peptide and protein identification 
Paper I. Peptide identification from the MALDI-TOF/TOF data was carried 
out by using the Paragon algorithmin and the ProteinPilot 2.0 software 
package (Applied Biosystems). Default settings for a 4800 instrument were 
used (i.e., no manual settings for mass tolerance were given). The following 
parameters were selected in the analysis: iTRAQ 8-plex peptide labeled as 
sample type, MMTS as alkylating agent of cysteine, trypsin as digesting 
enzyme, 4800 as instrument, biological modifications as ID focus, and 
through ID as search effort. Searches were performed against the IPI 
database (build 3.60) limited to rat sequences. False discovery rate was 
estimated by searching the data against a database consisting of both 
forward and reversed sequences. 
Paper II. All Orbitrap data were searched by Sequest-percolator under the 
software platform Proteome Discoverer 1.3 (Thermo Fischer Scientific) 
against the Uniprot rat canonical sequence protein database (27,316 
entries, December 2013) using a 1 % false discovery rate cutoff. A precursor 
mass tolerance of 10 ppm, and product mass tolerances of 0.02 Da for HCD-
FTMS and 0.8 Da for CID-ITMS were used. Further settings used were: 
trypsin with 1 missed cleavage; iodoacetamide on cysteine, iTRAQ 8-plex on 
lysine, and N-terminal as fixed modifications; oxidation of methionine as 
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variable modification. Quantification of iTRAQ 8-plex reporter ions was done 
by Proteome Discoverer on HCD-FTMS tandem mass spectra using an 
integration window tolerance of 20 ppm. Only unique peptides in the data 
set were used for quantitation. 
4.3.6 Data distribution and extraction of regulated proteins 
Paper II. Lists of differentially expressed proteins were extracted by the use 
of GraphPad Prism 5 and Excel. To investigate the distribution of the data 
and the ratio between the replicates, the data were plotted using GraphPad 
Prism 5. The ratio between the 0 replicate time points in the Thapsigargin 
data set were larger than the Palmitate data set, and Thapsigargin data 
were therefore used to calculate the cut off for the both data sets. The 
standard deviation for Thapsigargin gives a 95% confidence interval 
between 0.77-1.3, which is used as cut off for regulated proteins. For a 
protein to be defined as regulated, both replicates have to reach the cut off 
level. To avoid extraction of false positive proteins, proteins in the 0-time 
points with a ratio less than 0.77 and more than 1.3 were excluded from the 
list of regulated proteins. 
4.3.7 Bioinformatic analysis 
4.3.7.1 Gene Ontology and enrichment analysis 
The Gene Ontology (GO) is a widely used biological ontology [149]. The GO 
consortium is an effort to standardize the annotations of genes and gene 
products by using a controlled and structured vocabulary of terms. One 
common application of the GO vocabulary is in the enrichment analysis 
where significantly overrepresented GO terms, in a given set of genes or 
gene products, are identified. GOrilla is a web-based application tool that 
identifies enriched GO terms in a ranked list of genes [150]. Our list of 
regulated proteins at each time point (the target set) were imported into 
the application tool and searched against all identified proteins in our data 
sets (the background set) for enrichments. The threshold p-value was set to 
p < 10-3. 
4.3.7.2 Analysis of transcription factors in Ingenuity Pathway Analysis 
The web-based software from Ingenuity Systems (Ingenuity Pathway 
Analysis, IPA, www.ingenuity.com) was used for the search of regulated 
transcription factors in the Upstream Regulator tool. The upstream 
regulator analysis is based on prior knowledge of expected effects between 
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transcription regulators and their target genes in the IPA Ingenuity® 
Knowledge Base. This tool analyses how many known targets of each 
transcription factor are present in the data set and how they are regulated. 
This is compared to the literature to predict the activation status of a 
transcription factor. For each transcription factor, an overlap p-value and a 
z-score are computed. The overlap p-value measures if there is a statistically 
significant overlap between the genes in the data set compared to known 
targets of the transcription factor, measured by Fisher´s Exact Test. The 
purpose of the z-score is to measure the predicted activation status of each 
transcription factor. 
4.4 ASSESSMENT OF APOPTOSIS AND CELL VIABILITY 
The Cell Death Detection Kit ELISAPLUS (Roche Diagnostics) was used to 
monitor apoptosis induced by the treatment (paper I, II and III). After 
exposure, cells were washed twice in PBS and lyzed in buffer included in the 
kit. Apoptosis was detected by measuring cytoplasmic DNA-histone 
nucleosomes, generated during apoptotic DNA fragmentation, according to 
the manufacturer’s instructions. 
Cell viability was assessed by the Cytotoxicity Detction KitPlus (Roche 
Diagnostics) (paper III). After exposure, cells were washed twice with PBS 
and lyzed in PBS supplemented with 1% Triton X-100. The amount of lactate 
dehydrogenase released after cell lysis correlates with the amount of living 
cells after treatment. 
4.5 RNA EXTRACTION, CDNA SYNTHESIS AND 
QUANTITATIVE RT-PCR 
Quantitative real-time Polymerase Chain reaction (PCR) was used in paper I 
and III for quantification of mRNA levels of GRP78/BiP, PDIA3, CHOP, 
Gadd34, Cdkn1a, Sgk1. After exposure, total RNA was isolated using 
AurumTM Total RNA Mini kit (BioRad Laboratories). Total RNA was reverse 
transcribed using iScriptTM cDNA Synthesis kit (BioRad Laboratories). The 
resulting cDNA was used for real-time PCR analysis using Maxima™ SYBR 
Green/Fluorescein qPCR Master Mix (Fermentas, Burlington, ON, Canada) 
(paper I) or SYBR Green Master mix (Thermo Scientific, Waltham, MA) 
(paper III). Amplification of the sequence of interest is achieved by using 
specific primers. The amplification is driven by a series of repeated 
temperature cycles consisting of three steps; 1) Denaturation (95 °C) where 
double stranded DNA dissociates through disruption of hydrogen bonds, 2) 
Annealing (50 °C) when the primers base pair with the template DNA, and 3) 
Elongation (72 °C) when the DNA polymerase synthesize a new DNA strand. 
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In quantitative real-time PCR the progression of the amplification is 
measured after each completed cycle by the use of SYBR Green which 
recognizes and binds to double stranded DNA. When binding, SYBR Green 
emits light upon excitation. The number of cycles needed to reach the 
threshold is dependent of the amount of mRNA in the original sample and 
can be used for relative comparison between samples.  
Normalization was performed using the housekeeping gene Rattus 
norvegicus ribosomal protein L13A (Rpl13a), whose expression is not 
modified by thapsigargin (paper I) and β-actin (paper III). 
The following formula was used for quantification: target amount = 2 – ΔΔCt, 
where ΔΔCt = (Cttarget gene – Cthousekeeping gene)Sample – (Cttarget gene – Cthousekeeping 
gene)Control [151]. 
4.6 MEASUREMENT OF XBP-1 SPLICING 
For investigation of splicing of XBP-1 mRNA (paper I), total RNA was isolated 
and cDNA synthesized from INS-1E cells as described above. Rat XBP-1 cDNA 
was amplified using iProof Master Mix (Fermentas) and XBP-1 primers, 
flanking the 26 bp splicing site, which contains a PstI restriction site 
(CTGCAG). The PCR product was incubated with PstI (Fermentas) for 30 min 
at 37 °C and the digested product was separated on a 2% agarose gel and 
visualized using ethidium bromide. The gel shows one band at 746 bp for 
spliced XBP-1 and two bands at 458 bp and 314 bp for non-spliced XBP-1. 
4.7 TRANSFECTION WITH SMALL INTERFERING RNA 
Small interfering RNA (siRNA), used in paper I and III, is a short sequence 
(21-23 nucleotides) of double stranded RNA. The method is used to reduce 
the cellular level of a specific mRNA sequence. The sequence of the siRNA 
matches the sequence of the target mRNA in the cell. In paper I, a mixture 
of four different siRNA against Apg5 was used (Dharmacon RNAi 
Technologies, Thermo Fisher Scientific, Aalst, Belgium). 100 pmol of siRNA 
(25 pmol per siRNA) were introduced into INS-1E cells via nucleofection with 
a Nucleofector® II (Lonza, Basel, Switzerland) using Solution V and program 
T-20. As negative control, a non-targeting siRNA was used (Dharmacon). 
Exposure of cells started 48 hours post transfection. In paper III, siRNA 
targeting three different regions of mouse Ppp5c mRNA (Santa Cruz 
Biotechnology) were used. 100 pmol were introduced into MIN6 cells via 
nucleofection with a Nucleofector® II using Solution V and program G-16. As 
negative control, a non-targeting siRNA was used (Santa Cruz 
Biothechnology). 
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4.8 ASSESSMENT OF PROTEIN SYNTHESIS 
To monitor protein synthesis (paper I), cells were exposed followed by 
starvation in a medium lacking L-methionine and L-cysteine for 1 hour. Next, 
Met-[35S]-label IS-103 isotope, (Biotech-IgG, Denmark) was added and cells 
were left for one additional hour. After labeling, cells were harvested, lyzed 
and radioactivity was measured in equal protein loads in a β–counter 
(Perkin-Elmer). 
4.9 STATISTICAL ANALYSIS 
Data from all used methods, except for the MS data, are presented as 
means ± s.e.m. Comparisons were performed by using Student’s t-test or 
one-way ANOVA with Dunnett post-hoc test using GraphPad Prism 5. A P -
value < 0.05 was deemed as statistically significant. 
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5 RESULTS AND DISCUSSION 
T2DM is associated with a reduced function [43] and mass [50] of the 
pancreatic β-cells, but the exact mechanisms for the pathogenesis of the 
disease is still not known. As a secretory cell, the β-cell is equipped with a 
highly developed ER, to assist in the folding process of newly synthesized 
proteins [70, 75], and a proper function of this organelle is especially 
important in the face of an increased demand of insulin, as in the condition 
of insulin resistance and obesity. The general aim of this thesis was to 
investigate the protein expression in insulin producing cells exposed to 
endoplasmic reticulum stress and explore possible mechanisms involved in 
the progression of the reduced β-cell function and β-cell mass seen in type 2 
diabetic patients. 
5.1 PAPER I 
Thapsigargin down-regulates protein levels of GRP78/BiP in INS-1E cells 
Accumulation of misfolded proteins in the ER initiates activation of three 
distinct pathways of the UPR to restore the homeostasis in the ER [76, 77]. 
PERK and IRE1 pathways have been shown to transduce cytotoxic signals, 
eventually leading to apoptosis, while ATF6 pathway is considered to 
provide cytoprotection through up-regulation of chaperones [152, 153]. The 
ER contains numerous protein chaperones to assist the folding process of 
newly synthesized proteins [70, 75]. The ER chaperone GRP78/BiP is a 
central regulator of ER stress, as it controls the activation of the three 
transmembrane ER stress transducers. A commonly used chemical to induce 
ER stress and the UPR in experimental systems is the 
sarcoplasmic/endoplasmic Ca2+-ATPas (SERCA) pump inhibitor thapsigargin, 
which blocks uptake of calcium ions to the ER [87, 154]. We observed that 
exposure of INS-1E cells to thapsigargin decreased the protein levels of 
GRP78/BiP instead of the expected increase. In paper I we investigate by 
which mechanisms thapsigargin decreased GRP78/BiP protein in these cells. 
A second aim of this paper was to investigate the chaperone expression 
during an ER stress response, induces by thapsigargin in INS-1E cells, by the 
use of quantitative mass spectrometry based proteomics. 
From the positively identification and quantification of 269 unique proteins, 
8 were classified as chaperones, 2 as protein disulfide isomerases (PDIs) and 
2 as peptidylprolyl isomerases. The chaperones heat shock protein 90β and 
GRP78/BiP, and the 2 PDIs, PDIA3 and PDIA6, showed all a time-dependent 
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decrease after treatment with thapsigargin. GRP78/BiP, PDIA3 and PDIA6 
are all localized to the ER while heat shock protein 90β is cytoplasmic. 
Validation of the protein expression of GRP78/BiP with Western blot 
corroborated proteomics data after thapsigarin treatment. In parallel with 
decreased protein levels of GRP78/BiP, we could see a clear induction of ER 
stress with enhanced phosphorylation of eIF2α (p-eIF2α), elevated protein 
levels of CHOP and enhanced splicing of XBP1. As expected, thapsigargin 
induced apoptosis, evident by elevated levels of cleaved caspase 3 and 
increased DNA fragmentation. The reduced protein levels of GRP78/BiP and 
PDIA3 are not a consequence of reduced mRNA expression since the mRNA 
levels of GRP78/BiP were increased and mRNA levels of PDIA3 were 
unaffected by the treatment with thapsigargin in the INS-1E cells. 
One consequence of induced ER stress, by the PERK pathway of the UPR, is 
inhibition of the protein synthesis [155]. To test the hypothesis that 
inhibition of protein synthesis causes the reduced protein levels of 
GRP78/BiP, we used the protein synthesis inhibitor cycloheximide. Used 
concentrations of cycloheximide and thapsigargin caused a similar inhibition 
of protein synthesis. However, the GRP78/BiP levels were only slightly 
decreased after inhibition of protein synthesis and therefore we conclude 
that inhibition of protein synthesis by thapsigargin only explain a small part 
of the decreased levels of GRP78/BiP after treatment with SERCA inhibitor. 
We therefor investigated if the decrease of GRP78/BiP were a concequence 
of increased protein degradation by either the proteasome or by autophagy. 
Induction of ER stress enhances the ERAD pathway via the IRE1 pathway of 
the UPR, which directs misfolded proteins for destruction by the ubiquitin-
proteasome pathway [90]. The activity of the proteasome can be inhibited 
by lactacystin [92]. Co-treatment of INS-1E cells with thapsigargin and 
lactacystin showed decreased levels of GRP78/BiP. The decrease were  
however smaller than by treatment with thapsigargin alone. The result 
indicates that proteasomal degradation contributes to parts, but not all, of 
the decreased levels of GRP78/BiP. Another pathway for cellular protein 
degradation is autophagy. Investigation showed that treatment with 
thapsigargin induced autophagy in INS-1E cells evident by increased mRNA 
levels of Atg5 and conversion of LC3B-I to LC3B-II. To elucidate the 
degradation of GRP78/BiP by autophagy we used the autophagy inhibitor 3-
MA which inhibits the autophagosome formation by inhibiting type III 
Phosphatidylinositol kinases [156]. Analysis showed that the combinded 
treatment with thapsigargin and 3-MA gave a small decrease compared to 
treatment with thapsigargin alone, suggesting that degradation by 
autophagy can explain a small part of the decreased levels of GRP78/BiP 
after treatment with thapsigargin. 
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Since induction of chaperone expression occurs to maintain function of ER 
during an stress response, the data in paper I provides an explanation to 
why  INS-1E cells are vulnerable to conditions of ER stress. Comparison of 
the protein levels of GRP78/BiP, and the ER stress markers CHOP and p-
eIF2α, in MIN6 cells and isolated islets from mouse and rat, with the levels 
obtained in INS-1E cells reveals a less pronouneced induction of ER stress 
and not the same decrease of GRP78/BiP. The absence of decreased 
GRP78/BiP in MIN6 cells and islets, compared to INS-1E cells after 
thapsigargin treatment, may explain why INS-1E cells are sensitive to 
conditions of ER stress [86, 157]. Over expression of GRP78/BiP in INS-1E 
cells has been shown to reduce the suseptibility to thapsigargin-induced 
apoptosis [157], showing the importance of a functional chaperone 
response. 
To conclude our findings in paper I, we could see a decrease of GRP78/BiP, 
PDIA3 and PDIA6 protein levels in INS-1E cells following thapsigargin 
treatment. Investigation of the mechanisms behind the decreased protein 
levels of GRP78/BiP indicates that this is not a concequence of reduced 
mRNA expression. Rather, the reduction results from the combined effect of 
reduced protein synthesis and enhanced proteasomal degradation, and 
possibly also degradation via autophagy. Induction of ER stress by 
thapsigargin leads to lower protein levels of GRP78/BiP, PDIA3 and PDIA6 in 
INS-1E cells which may contribute to the suceptibility to ER stress in this β-
cell model. 
5.2 PAPER II 
Metabolic Master Transcription Factors affected by treatment with 
Palmitate and Thapsigargin - A Proteomic Investigation of the Insulin-
Producing Cell Line INS-1E 
T2DM is closely associated with obesity [158], where affected individuals 
display alterations in the circulating lipid profile [18, 19]. There is evidence 
that the elevated systemic levels of FAs are detrimental to pancreatic β-cells 
which may contribute to the progression of β-cell failure via both impaired 
function and a reduction of the β-cell mass seen in T2DM patients [21, 22, 
49, 50]. Investigations indicate that the reduced β-cell mass may be a result 
of increased apoptosis [30, 51, 65], but the mechanism is not completely 
known. There is evidence that saturated FAs can induce apoptosis [51, 52, 
159], as well as ER stress [70, 160]. This organelle is sensitive to alteration in 
homeostasis, and an imbalance between protein load and folding capacity 
can result in ER stress. In paper II we investigated the cellular protein 
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changes that occurred in the pancreatic β-cell line INS-1E exposed to the 
saturated FA palmitate and compare those to changes induced by the ER 
stress inducer thapsigargin. To this end we used quantitative mass 
spectrometry based proteomics. 
Before the proteomic experiment, we established conditions where 
palmitate and thapsigargin induced the same degree of apoptosis, evident 
by DNA fragmentation (Fig.6). Western blot data confirm that the used 
concentrations of palmitate and thapsigargin induce ER stress, by measuring 
CHOP and phosphorylation of eIF2α, although thapsigargin was shown to be 
a more potent inducer of ER stress than palmitate at these concentrations 
(Fig.6). 
 
Figure 6. Treatment with thapsigargin or palmitate induces apoptosis and ER 
stress in INS-1E cells. Cells were exposed to 200 nM thapsigargin or 0.4 mM 
palmitate for indicated time points. (A) Apoptosis was evaluated after 16 hours of 
treatment by using a cell death detection ELISA kit, measuring the levels of 
cytoplasmic oligonucleosomes. The data were normalized to the control condition. 
Bars represent mean ±SEM, n = 9. *P<0.05. (B, C) Blots showing protein levels of 
cleaved caspase 3, CHOP and phosphorylation status of eIF2α. 
 
In previous investigations of proteome changes in β-cells following ER stress, 
induced by cyclopiazonic acid, only a limited number, 34-101, of 
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differentially expressed proteins were identified [143], while exposure to 
palmitate resulted in detection of 5 to 19 differentially regulated proteins 
[67, 144, 146]. To increase the number of detected proteins, we reduced 
the complexity of the sample by narrow range isoelectric focusing [161] 
before nano-LC-MS/MS analysis. The time series data from thapsigargin- 
and palmitate data sets resulted in identification of 7,786 proteins of which 
6,117 were quantified in both data sets. In total, 1,088 proteins were 
considered to be regulated by any of the treatments in at least one of the 
time points examined. 1,000 proteins were up- or down-regulated by 
thapsigargin and 227 were affected by palmitate. Thus, during the 
experimental setting employed in this study, the proteomic changes 
induced by thapsigargin exceeded those induced by palmitate. 
Among the regulated proteins by thapsigargin and palmitate, a significant 
portion was localized to ER, in concordance with induction of UPR. Of all 
1,088 regulated proteins, 136 were GO annotated to ER. Of these proteins, 
108 were only affected by treatment with thapsigargin. Palmitate treatment 
affected 22 ER proteins, of which 15 also were affected by thapsigargin (12 
down-regulated and 3 up-regulated). Of the 7 proteins specifically affected 
by palmitate, 4 were down-regulated and 3 up-regulated. ER-localized 
proteins were enriched at all tested time points after treatment with 
thapsigargin, while ER proteins were enriched only after 24 hours treatment 
with palmitate. This corroborated the findings that thapsigargin induced a 
more rapid effect on ER compared to palmitate, as indicated by the stronger 
induction of ER stress seen in Western blot data. 
In our search for potential biological processes shared by thapsigargin and 
palmitate treatment in our data sets, we searched for regulated 
transcription factors, using Ingenuity Pathway Analysis (IPA) software. In this 
analysis we found that both thapsigargin and palmitate inhibited sterol 
regulatory element-binding protein (SREBP) -1 and SREBP-2 which are 
regulators of genes involved in FA- and cholesterol synthesis [162]. 
Furthermore, the transcription factor forkhead box protein O1 (FOXO1), 
involved in regulation of the cell cycle, apoptosis, autophagy and 
metabolism [163], as well as forkhead box protein M1 (FOXM1), a regulator 
of the expression of cell cycle genes essential for DNA replication and 
mitosis [164], were both predicted to be inhibited by thapsigargin and 
palmitate. 
 The rapid decrease of SREBP-2 by thapsigargin, seen in proteomics data, 
was validated by Western blot. As predicted by IPA, Western blot data 
confirms the inhibition of SREBP-2 activity by thapsigargin, while treatment 
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with palmitate induces an early, transient activation. Western blot data also 
show decreased levels of SREBP-1 precursor by thapsigargin while the levels 
were increased after palmitate treatment. None of the treatments activated 
SREBP-1, confirming the predicted activation status by IPA. It has been 
reported that treatment of INS-1E cells not activates SREBP-1 in response to 
FAs [165]. In addition, inhibition of transcription factors and pathways 
involved in lipid and cholesterol metabolism have been reported in liver 
after induction of ER stress with tunicamycin [166, 167]. Palmitate was also 
reported to decrease SREBP-1 levels in hepatocytes [168]. On the other 
hand, SREBP-1 has been reported to be increased in liver and islets of 
diabetic animals [169]. One suggestion for the increased SREBP-1 levels in 
the diabetic animals is that the hyperglycemia, rather than the FAs, causes 
the increase since glucose has been shown to activate this transcription 
factor [165]. 
In paper II we identified 6,117 unique proteins expressed in INS-1E cells, 
making this study one of the most detailed proteomic studies of insulin 
producing cells. Treatment with the saturated FA palmitate and the SERCA 
pump inhibitor thapsigargin shared a profound effect on UPR and ER 
localized proteins. The results also show that palmitate and thapsigargin 
down-regulates proteins involved in biosynthesis of cholesterol and FAs, as 
well as proteins involved in cell cycle regulation. The treatments not only 
share the induction of ER stress but also share an effect on the lipid handling 
in the cell. 
5.3 PAPER III 
Mitogen-activated protein kinases and protein phosphatase 5 mediate 
glucocorticoid-induced cytotoxicity in pancreatic islets and β-cells. 
Glucocorticoid (GC) excess is associated with glucose intolerance and 
diabetes by mechanisms including, increased gluconeogenesis in the liver, 
decreased uptake of glucose into muscle and adipose tissue, breakdown of 
muscle and lipids to provide additional substrates for glucose production, 
and inhibition of insulin secretion from pancreatic β-cells [116-118]. The 
direct effect of GCs on pancreatic β-cells and islets is difficult to study during 
in vivo conditions since the metabolic actions of GCs interfere with the 
direct effects induced by GCs. Investigations in isolated islets and pancreatic 
β-cell lines have shown that exposure to GCs are toxic to these cells [122-
124] but how the GCs exert their cytotoxic action in the β-cells is not fully 
understood. Investigations have shown that dysfunction of ER homeostasis 
[125] and MAPK activation might contribute to the cytotoxic effect in β-
  45 
cells, induced by GCs [124]. The action of protein kinases are countered by 
protein phosphatases, and the phosphatase activity of the GC receptor (GR) 
have been shown to be catalyzed by protein phosphatase 5 (PP5) that binds 
to GR via interaction with heat-shock protein 90 [170, 171]. In paper III we 
investigate pathways involved in the cytotoxic action of GCs and the role of 
MAPKs and PP5 in this process in pancreatic β-cells and islets. 
As expected, exposure of MIN6 cells to different synthetic GCs reduced the 
viability of the cells, and exposure of MIN6 cells and isolated mouse islets to 
dexamethasone induced apoptosis, evident by DNA fragmentation. The 
cytotoxic effects induced by the GCs were reversed by the GR antagonist 
RU486. To gain insight into the cytotoxic action induced by GCs we 
investigated  ER stress and the PERK pathway of the UPR, by measuring p-
eIF2α, and mRNA expression of the pro-apoptotic genes CHOP and GADD34, 
in MIN6 cells exposed to dexamethasone. The result showed a reduced 
phosphorylation of eIF2α, as previously shown [125], as well as decreased 
mRNA levels of CHOP and GADD34, indicating a reduced activity of this 
pathway of the UPR. Activation of the PERK pathway of the UPR acts to 
alleviate the ER stress by reducing the protein translation, and thereby 
reduce the influx of proteins into ER [77]. Our result indicate a compromised 
activity of the UPR following treatment with dexamethasone, which may 
lead to a reduced capacity to restore the homeostasis in the ER. Failure to 
induce UPR has been linked to abnormalities in β-cell gene expression and 
progression towards diabetes in db/db mice [172]. 
To further explore the cytotoxic effects inducd by dexamethasone in MIN6 
cells, we investigated the MAPK siganaling pathway. The MAPK proteins p38 
and JNK are known to regulate cell differentiation and apoptosis and have 
been shown to be activated by various forms of environmental stress and 
inflammation [173]. We observed an increased phosphorylation of both p38 
and JNK, following treatment with dexamethasone, an effect that was 
reversed by RU486. Further investigation showed that p38 and JNK, as well 
ASK-1, an upstream kinase activating both p38 and JNK [173], were 
phosphorylated by dexamethasone in an time-dependent manner. 
Pharmacological inhibition of p38 MAPK, by SB203580 in MIN6 cells, 
attenuated dexamethasone-induced DNA fragmentation and impoved the 
viability of the cells. In addition, dexamethasone-induced induction of 
cleaved caspase 3, in isolated islets from mice, was prevented by SB203580 
alsmost to the same extent as with RU486. It has been demonstrated that 
p38 MAPK phosphorylates GR at serine 220 (corresponding to serine 211 in 
human) which stimulates the activity of the GR [174]. We could see that 
exposure of MIN6 cells to dexamethasone induced phosphorylation att 
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serine 220, an effect that to some extent was reversed by SB203580, 
suggesting a contribution of p38 MAPK phosphorylation at serine 220 of the 
GR, in the cytotoxcicity induced by dexamethasone. In contrast to the 
protective effect by inhibition of p38 MAPK, the JNK inhibitor SP600125 
agumented the dexamethasone-induced apoptosis. It has been 
demonstrated that JNK is responsible for phosphorylation of serine 234 of 
the GR which leads to a loss of GR action [175]. We could also show that the 
effect of JNK inhibition is dependent on a functional GR since inhibition of 
GR abolished the agumenting effect off SP600125 on dexamethasone-
induced apoptosis. 
The activity of GR is not only regulated by kinases, but also by phosphatases. 
The phosphatase PP5 has been shown to decrease phosphorylation of GR at 
serine 220/211, resulting in a reduced sensitivity to GC treatment in airway 
smooth muscle cells [176]. In addition, suppression of PP5 has shown to 
increas the transcriptional activity of GR [171], supporting a role for PP5 as a 
regulator of GR activity. We show that MIN6 cells and islets with reduced 
levels of PP5 display increased suseptibility to dexamethasone-induced 
apoptosis. In addition, the GC-induced phosphorylation of p38 MAPK is 
agumented in cells and islets lacing PP5, suggesting that PP5 function as a 
mediator of β-cell protection against GC-induced cytotoxicity. 
In conclusion, our data show that dexamethasone activates ASK-1 and its 
downstream targets p38 MAPK and JNK in β-cells, which work in opposite to 
regulate the cytotoxic effects induced by GCs. The data also suggests that 
PP5 play a protective role, since reduced PP5 levels in MIN6 cells and islets 
makes the cells sensitized to the toxic effects induced by GCs. Our results 
also indicate a compromised activity of the UPR, which may lead to a 
reduced capacity to restore the homeostasis in the ER. 
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6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
6.1 CONCLUDING REMARKS 
The prevalence of T2DM is increasing rapidly worldwide as a result of the 
obesity epidemic, and is associated with severe and long-term 
complications of affected individuals, as well as an enormous economic 
burden to health care systems. It is therefore of great importance to 
elucidate the mechanisms contributing to the progression of the disease. 
There is evidence that the elevated levels of FAs are detrimental to 
pancreatic β-cells which may contribute to the progression of β-cell failure 
via both impaired function and a reduction of the β-cell mass seen in T2DM 
patients. Saturated FAs can induce apoptosis, as well as ER stress. As a 
secretory cell, the pancreatic β-cell is equipped with a highly developed ER 
to assist in the folding process of newly synthesized proteins, but this cell 
organelle is sensitive to alteration in homeostasis, and an imbalance 
between protein load and folding capacity can result in ER stress. This thesis 
aimed to investigate the protein expression in insulin producing cells 
exposed to ER stress. In paper I, levels of the ER localized protein 
GRP78/BiP, PDIA3 and PDIA6 were decrased by thapsigargin  in INS-1E cells. 
The decrease involved a combination of reduced protein synthesis and 
enhanced degradation by both proteasome and autophagy. The data in 
paper I provides an explanation to why  INS-1E cells are vulnerable to 
conditions of ER stress. In paper II, we identified 7,786 proteins by the use 
of proteomic in INS-1E cells exposed to palmitate and thapsigargin. 1,000 
proteins were regulated by thapsigargin and 227 by palmitate. Bioinformatic 
analysis revealed a set of transcription factors predicted to be regulated in 
the same manner by the thapsigargin and palmitate. This paper shows that 
the treatments not only share the induction of ER stress but also share an 
effect on the lipid handling in the cell by affecting several metabolic master 
transcription factors. 
In addition to increased prevalence of T2DM and obesity, the prevalence of 
metabolic syndrome is also increasing. This condition is associated with 
increased risk of developing T2DM. In addition, individuals suffering from 
metabolic syndrome have been shown to have elevated levels of cortisol 
and therefore, in paper III we wanted to investigate pathways involved in 
the cytotoxic action of GCs since excess of GCs is associated with glucose 
intolerance and diabetes. The data show that GC activates p38 MAPK and 
JNK in β-cells, which work in opposite to regulate the cytotoxic effects 
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induced by GCs. The data also suggests that PP5 play a protective role, since 
reduced PP5 levels in MIN6 cells and islets makes the cells sensitized to the 
toxic effects induced by GCs. Our result also indicate a GC-induced 
compromised activity of the UPR, which may lead to a reduced capacity to 
restore the homeostasis in the ER. 
6.2 FUTURE PERSPECTIVES 
The time series data from the proteomics analysis in paper II resulted in 
identification of 7,786 proteins in two independent data sets. 1,000 proteins 
after treatment with thapsigargin and 227 proteins after treatment with 
palmitate were found to be either up- or down-regulated in at least one 
time point. It would be of interest to further investigate the proteins 
affected by the treatments. Tools such as siRNA mediated knock down of 
mRNA expression, as well as vectors used for induced over expression 
would certainly be important tools to elucidate functional consequences of 
these proteins. It is possible to investigate which pathways and networks 
the regulated proteins are involved in. Categorization by cellular localization 
of all regulated proteins can also be done to investigate where in the cell, 
apart from the ER, the regulated proteins are localized. Categorization of 
biological function and cellular processes of the regulated proteins would 
also be possible. Another interesting aspect to analyze in the data sets are 
proteins affected at the early time point and compare those to proteins 
affected at a later time point. 
A deeper investigation of the proteins affected by the treatments would be 
of great value, since both ER stress and FAs are implicated in the 
dysfunction of β-cells in the progression to T2DM. 
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7 SVENSK SAMMANFATTINING 
Antalet människor som drabbas av typ 2 diabetes ökar i hela världen. Denna 
ökning går hand i hand med en ökad förekomst av övervikt och fetma. Vår 
västerlänska livsstil med ett högt kaloriintag tillsammans med att vi rör oss 
för lite är en farlig kombination. Typ 2 diabetes känneteckans av att den 
drabbade inte kan kontrollera sin blodsockernivå, vilket på sikt kan leda till 
komplikationer. Nivåerna av socker i blodet registreras av β-celler som finns 
i bukspottkörteln. De svarar på en ökad sockernivå genom att producera 
och utsöndra insulin till blodet. Insulinet behövs för att muskler och fett ska 
kunna ta upp socker. Detta leder till att nivåerna av socker sjunker till det 
normala i blodet. Hos en typ 2 diabetiker klarar inte β-cellerna av att 
utsöndra tillräckligt med insulin för att sänka blodsockernivåerna. 
Studier har visat att typ 2 diabetiker har en försämrad funktion hos β-
cellerna, men även en ökad β-cellsdöd. Vad som orsakar denna försämring 
är inte helt klarlagd. Individer som lider av fetma har ökade nivåer av 
fettsyror i blodet och man har sett att fettsyror kan leda till försämrad 
funktion och död hos β-cellerna. Man har även sett att fettsyror kan leda till 
sk endoplasmatisk retikulum stress (ER stress), något som uppstår då cellen 
inte förmår att bearbeta (vecka) nybildade proteiner, som t.ex. insulin, så att 
de antar sin rätta form. Cellen försöker då skydda sig genom att öka tre 
signaleringsvägar som tillsammans kallas ER stressrespons. Om detta försök 
misslyckas aktiverar cellen istället siganleringsvägar för celldöd. 
Forskningen som ligger till grund för denna avhandling har undersökt 
proteinnivåer hos insulinproducerande celler som exponerats för ER stress. I 
studie I använde vi oss av en teknik som kallas proteomik. Denna teknik kan 
användas för att studera i princip alla proteiner i cellen på en och samma 
gång. Syftet med proteomikundersökningen var att undersöka proteiner 
som hjälper till i veckningsprocessen. Insulinproducerande celler utsattes för 
en substans som inducerar ER stress innan undersökningen. 
Undersökningen visade att tre av de identifierad proteinerna som hjälper till 
i veckningsprocessen var minskade när cellen utsattes för ER stress. 
Fortsatta undersökningar av ett av dessa proteiner visade att de minskade 
nivåerna beror på att att cellen minskar syntesen av proteinet, i 
kombination med en ökad nedbrytning genom två olika processer. Studien 
visar att en fungerande veckningsprocess krävs för att cellen ska överleva. 
Även i studie II använde vi proteomiktekniken. Celler exponerade för den 
mättade fettsyra palmitat jämfördes med celler exponerade för den ER 
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stressinducerande substansen. I denna studie identifierade vi 7,786 
proteiner. Av dessa var 227 ökade eller minskade efter exponering för 
fettsyran, medan 1,000 var ökade eller minskade efter exponering för den 
ER stressinducerande substansen. Fortsatta analyser visade en grupp 
regleringsproteiner som påverkas på samma sätt av de båda 
behandlingarna. Denna studie visde att både den mättade fettsyran och ER 
stressinduceraren orsakar ER stress i cellen, samtidigt som båda även 
påverkar fettmetabolismen i cellen genom att påverka 
regleringsproteinerna på ett likartat sätt. 
Samtidigt som typ 2 diabetes och fetma ökar i världen så ökar även det 
”metabola syndromet” vilket är ett samlingsnamn för olika riskfaktorer för 
ämnesomsättningssjukdom. Det metabola syndromet är förknippat med en 
ökad risk att drabbas av hjärt-kärlsjukdomar och typ 2 diabetes. Det har 
visats att individer med metabola syndromet har ökade nivåer av kortisol i 
blodet. Kortisol tillhör en grupp steroidhormoner som kallas 
glukokortikoider. En rad läkemedel är baserade på glukokortikoider och de 
används t.ex för att dämpa allergiska reaktioner. En biverkan hos denna typ 
av läkemedel  är symptom förknippade med metabola syndromet och även 
utveckling av diabetes. I studie III kunde vi se att β-celler exponerade för 
glukokortikoider dog. Vi ville därför undersöka vilka signaleringsvägar som 
var förknippade med de negativa effekter på cellen efter 
glukokortikoidbehandling. Vi såg att ett protein, proteinfosfatas 5, var viktig 
för att reglera effekten av glukokortikoider. Vi kunde visa att om detta 
protein saknas blir cellerna extra känslig för de negativa effekterna som 
glukokortikoiderna ger. 
Studier på insulinproducerande β-celler är nödvändig för att få en större 
förståelse för de mekanismer och faktorer som reglerar de negativa 
effekterna på dessa celler. Detta kommer förhoppningsvis i framtiden leda 
till verktyg för att bevara funktionen och mängden av β-cellerna, och på så 
sätt hindra eller fördröja utvecklingen av typ 2 diabetes. 
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